Developing therapeutics for ultra-rare pediatric neurodegenerative disorders is notoriously difficult. With small, geographically dispersed patient populations, rapid disease progression, and pronounced phenotypic heterogeneity, conventional parallel-group randomized controlled trials often fail due to insufficient statistical power and high dropout rates.
The FDA's standard approval of IntraBio's Aqneursa (levacetylleucine) for ataxia in ataxia-telangiectasia (A-T) marks a watershed moment for orphan drug development. In this deep dive, we examine how a meticulously executed 73-patient crossover trial published in The Lancet Neurology achieved regulatory approval, the underlying neuronal metabolic biology, and the emerging commercial playbook for multi-indication orphan assets.
